Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESTRO 2025 | The role of biomarker-driven tools in optimizing radiotherapy for breast cancer

Icro Meattini • 30 May 2025
ESTRO 2025
Breast Cancer

Icro Meattini, MD, University of Florence, Florence, Italy, emphasizes the significance of data from biomarker-driven tools in guiding radiation therapy decisions for breast cancer patients. Dr Meattini highlights that traditional radiotherapy approaches based on limited histopathological features may not accurately predict treatment effectiveness, leading to potential under or over-treatment. Having robust data on the predictive value of radiotherapy can help clinicians make informed decisions and provide optimal care for patients, particularly in cases where radiation therapy is being considered or omitted. This interview took place at the ESTRO 2025 congress in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Icro Meattini

Early breast cancer: multimodal de-escalation strategies to reduce treatment burden safely
5:20
Early breast cancer: multimodal de-escalation strategies to reduce treatment burden safely
Icro Meattini • 10 Jul 2025
BRCA carrier status and radiation therapy in young patients with breast cancer
2:34
BRCA carrier status and radiation therapy in young patients with breast cancer
Icro Meattini • 30 May 2025
Moderate hypofractionation in high-risk breast cancer
3:07
Moderate hypofractionation in high-risk breast cancer
Icro Meattini • 30 May 2025
BRCA1 and BRCA2 carrier status: implications for breast cancer treatment
1:28
BRCA1 and BRCA2 carrier status: implications for breast cancer treatment
Icro Meattini • 30 May 2025

Related Videos

CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals